Remove Genetic Analysis Remove Genomics Remove Medicine
article thumbnail

AI test could predict best cancer therapies for patients

pharmaphorum

The team has focused initially on non-small cell lung cancer (NSCLC), the most common form of lung cancer, but say the same principles could be applied to other tumour types, and combined with other testing approaches like genomics to inform treatment decisions.

Protein 67
article thumbnail

Solving the Global Clinical Trial Gap: The Case for Partnering with Multisite Lab Services

XTalks

Over the past several years, personalized medicine has led the charge in medical innovation, leading drug development efforts as well as furthering the research community’s understanding of human disease states.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genes Help Explain Role of Race in Prostate Cancer Risk

The Pharma Data

. “The potential utility of this is that it can be used to define men who are at elevated risk of developing prostate cancer,” said lead author Christopher Haiman, professor of preventive medicine at Keck School of Medicine at the University of Southern California (USC) in Los Angeles.

Gene 52
article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing.

DNA 52
article thumbnail

Top 10 Biotech Trends for 2025

XTalks

Whether its the integration of nanotechnology in medicine, the evolution of point-of-care (POC) diagnostics or the transformative impact of CRISPR and regenerative medicine, these biotech trends are pushing scientific boundaries and creating new opportunities for businesses and researchers alike. billion by 2032, with a CAGR of 10.1